vopimetostat
TNG462 Small Molecule Target: PRMT5
Tango Therapeutics
Most recent annual filing: 2026-03-05
- TNG456 Ph1 interim2026TNG456 Ph1 interim, 2026, material
- Vopimetostat monotherapy lung cancer Ph12H 2026Vopimetostat monotherapy lung cancer Ph1, 2H 2026, material
- TNG456 readout2H 2026TNG456 readout, 2H 2026, notable
- Vopimetostat monotherapy 2L PDAC pivotal2H 2026Vopimetostat monotherapy 2L PDAC pivotal, 2H 2026, routine
- vopimetostat + RAS ON Ph1Oct 23–27, 2026vopimetostat + RAS ON Ph1, Oct 23–27, 2026, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
Discontinued (3)
- TNG961 — undisclosed · deprioritized; no current plans to further advance development
- TNG260 — undisclosed · deprioritized; limited clinical benefit observed; plan to shut down the clinical trial
- TNG908 — Glioblastoma · stopped enrollment due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization
Biotech Distilled coverage (7)
- 2026-08-12 UPDATE: Tango Therapeutics (TNGX) - A Billion in the Bank and a Commercial Chief
- 2026-06-08 UPDATE: Tango Therapeutics (TNGX) - The Combo Hit. 92% ORR.
- 2026-05-16 UPDATE: Tango Therapeutics (TNGX) – Four Specialists, One Pile-On, and a 19% Two-Day Gap Down 🔒 Paid
- 2026-05-14 UPDATE: Tango Therapeutics (TNGX) – The Pipeline Just Got a Lot Smaller (and the Smart Money Got Bigger) 🔒 Paid
- 2026-05-12 UPDATE: Tango Therapeutics (TNGX) – Farallon Steps Into the Seat Third Rock Vacated 🔒 Paid
- 2026-04-18 UPDATE: Tango Therapeutics (TNGX) – The C-Suite Revolving Door Continues 🔒 Paid
- 2026-03-18 Tango Therapeutics (TNGX) - Scientific Deep Dive for Vopimetostat and Pipeline Products
Articles open on Substack. Some deep dives are subscriber-only.